minimizing fatigue and mistakes made by nurses who work night shifts.

Published Date: 26 Apr 2023

Researchers from McGill University found that nurses who receive 40 minutes of bright light exposure prior to their night shifts experience less fatigue and commit fewer mistakes. Following their shifts, the nurses also slept better.

Read Full News

Latest News

COPD in 2025: Year in Review

COPD in 2025: Year in Review

Characterizing COPD - Lung Cancer Patients, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Todays Updates

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study Isabella Ciccone, MPH

Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.

IgA Nephropathy in 2025: Year in Review

IgA Nephropathy in 2025: Year in Review

Todays Updates

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study Isabella Ciccone, MPH

Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.

IgA Nephropathy in 2025: Year in Review

IgA Nephropathy in 2025: Year in Review

Latest News

COPD in 2025: Year in Review

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

News All Time

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Recommended News For You

Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP

Lower screening age calls for more tailored bowel cancer surveillance

Should the UK introduce targeted prostate cancer screening? The case for and against

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

FDA approves rivanetin as the first-line treatment for lung cancer.

AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.

Recommended Articles For You

Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer 

Understanding Vaso Occlusive Crisis: Symptoms, Causes, and Management Strategies 

Effective Management Strategies for Sickle Cell Crisis: Insights from Medical Experts 

A New Hope: Exploring the Potential of Pegaspargase in Treating Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early palliative care billing up from 2010 to 2019 for advanced cancer

2.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

3.

Preventable pediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions

4.

Significant differences in breast cancer care still exist, but surgeons can change.

5.

Renewing the call for a national Cancer Patient's Bill of Rights

1.

Exploring New Treatment Options for Hemophilia: A Journey into the Unknown

2.

A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology

3.

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition

4.

What is Hemorrhagic Cystitis and How to Manage its Symptoms

5.

The Importance of Balanced Potassium Levels in Maintaining Good Health

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

3.

Thromboprophylaxis In Medical Settings

4.

Efficient Management of First line ALK-rearranged NSCLC - Part II

5.

Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot